Plain-English translation of NCT07053800 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Nephritis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new treatment called (Obe-cel) for people with severe lupus that has not improved with other medications and is actively attacking the kidneys. The medication works by using your own immune cells that have been genetically modified in the laboratory to help calm down the lupus. This is a Phase 2 trial, meaning the treatment has shown some promise in early studies and researchers now want to learn more about how well and safely it works.
Severe lupus that damages the kidneys (lupus nephritis) can be life-threatening, and some patients don't get better even after trying multiple standard treatments. Researchers are testing this new cell-based approach because it targets a specific part of the immune system in a different way than traditional medications, offering hope for people who have run out of other options.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will start with a screening visit to confirm your eligibility. You will then receive a treatment period where your immune system is slightly weakened (called lymphodepletion) to prepare your body, and then receive a single infusion of the medication on Day 1. After that, you will have regular follow-up visits over time so doctors can monitor how well the treatment works and watch for any side effects. The study team will check your kidney function, lupus activity, and overall health throughout your participation.
AI-generated summary from trial data · Aug 27, 2026 · Not medical advice
United States
Brazil